Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Mylan To Commence Formal Offer To Acquire Perrigo For US$60 In Cash And 2.2 Mylan Shares Per Perrigo Share

POTTERS BAR, England, April 24, 2015 /PRNewswire/ — On 8 April 2015, Mylan N.V. (NASDAQ: MYL) issued a Rule 2.4 announcement under the Irish Takeover Rules stating that it had made a non-binding proposal to acquire Perrigo (NYSE: PRGO; TASE) for US$205 in a combination of cash and Mylan stock for each Perrigo share. The Rule 2.4 […]

Read More »

Merck & Co. Poised To Enter Oral HCV Market Dominated by Gilead and AbbVie

Merck & Co., Inc. (MRK), announced yesterday the first data from the company’s Phase II/III clinical trial dubbed C-SURFER for a once-daily treatment for patients with advanced chronic kidney disease (CKD) that are also infected with chronic hepatitis C virus (HCV) genotype 1 (GT1). The C-SURFER trial demonstrated that a 12-week regimen of NS3/4A protease […]

Read More »

Innate Pharma Strikes Cancer Pact Worth $1.275 Billion With Pharma Giant AstraZeneca PLC

Marseille, France-based Innate Pharma announced today that it had inked a co-development and commercialization deal with AstraZeneca (AZN) and MedImmune. MedImmune is a wholly owned subsidiary of AstraZeneca. The deal will focus on pushing the development of anti-NKG2A antibody, IPH2201, also in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor created by MedImmune. The compound, […]

Read More »

Children of depressed mothers at risk for behavior problems

<span class="articleLocation”>(Reuters Health) – Children are more likely to develop behavioral or emotional problems if their mothers are chronically depressed, even if symptoms aren’t severe, a French study finds. While previous research has linked clinical depression in mothers to mood disorders and other health problems in their children, the current study is among the first […]

Read More »

Actavis Announces Topline Phase 3 Clinical Trial Results for Single-Dose DALVANCE® (dalbavancin) in the Treatment of ABSSSI

DUBLIN, April 24, 2015 /PRNewswire/ — Actavis plc (NYSE: ACT) today announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of DALVANCE with the same total dose given as  two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible […]

Read More »

RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain

LAVAL, Quebec and TARRYTOWN, N.Y., April 24, 2015 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a new indication for RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection for the treatment of […]

Read More »

U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C

NORTH CHICAGO, Ill., April 24, 2015 /PRNewswire/ — AbbVie (NYSE: ABBV) has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted priority review for the company’s, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV). The NDA is for the treatment of […]

Read More »

World’s first malaria vaccine moves closer to use in Africa

(Reuters) – The world’s first malaria vaccine, made by GlaxoSmithKline, could be approved by international regulators for use in Africa from October after final trial data showed it offered partial protection for up to four years. The shot, called RTS,S and designed for children in Africa, would be the first licensed human vaccine against a […]

Read More »

Aerie Pharma shares battered as eye drug fails study

<span class="articleLocation”>(Reuters) – Aerie Pharmaceuticals Inc lost nearly three-quarters of its value after the company said its lead experimental eye drug failed a late-stage study. The eye drop, Rhopressa, did not lower pressure inside the eye as much as timolol, a commonly prescribed drug, the company said. Increased pressure in the eye is often a […]

Read More »

U.S. cancer survival rates improving

  (This version of the Feb 19 story replaces paragraphs two, six and seven with new text to clarify that the statistics reflected the decline in risk of death from cancer, not an increase in survival.)   By Andrew M. Seaman (Reuters Health) – The proportion of people surviving years after a cancer diagnosis is […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom